The 20-year term patent titled, Biocatalytic Processes For The Preparation Of Substantially Stereomerically Pure Fused Bicyclic Proline Compounds, does not expire until 2029.
Codexis senior vice president Peter Seufer-Wasserthal said CodeEvolver platform is enabling breakthrough biocatalytic processes to produce pharmaceutical intermediates, in this case for the latest hepatitis-C therapeutics.
"This patent specifically provides exclusivity for the use of our novel biocatalysts and production processes in the manufacture of these key intermediates," Seufer-Wasserthal added.
"The ability to provide custom and high-performance manufacturing processes for our pharmaceuticals customers creates a competitive advantage for Codexis."